Alexion Pharma (ALXN) Tops Q4 EPS by 40c, Revenues Beat

February 4, 2021 8:05 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $2.96, $0.40 better than the analyst estimate of $2.56. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.52 billion.

  • 4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19
  • 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96
  • Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021
  • Received EU approval for ULTOMIRIS┬« (ravulizumab) 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & atypical hemolytic uremic syndrome (aHUS)
  • Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020

"In 2020, we delivered on our LEAD-EXPAND-DIVERSIFY strategy - progressing our commercial portfolio with multiple global regulatory approvals, and further building our pipeline, which now spans more than 20 development programs. I am so proud of our team's remarkable execution and perseverance amidst the uncertainties of COVID-19," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "We enter 2021 with significant momentum, a strong foundation and a promising future. I am confident we are well positioned to build on our success and further advance our mission of delivering life-changing medicines to people with rare diseases and devastating conditions in the coming months and once we become part of AstraZeneca."

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities